Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 354 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading February 12, 2026 Boy Born With Heart Defect Gets Surgery To Help It Triple... December 26, 2021 EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of... May 23, 2024 Delivering the future of paediatric brain tumour therapy October 7, 2021 Load more HOT NEWS Ahead of a Key Meeting of EU Health Ministers, ESMO Calls... Discovering the BRCA2 gene – 25 years on Digital Breast Tomosynthesis Found to Detect Invasive Cancers At a Higher... Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis
